BRIEF: Trip.com’s revenue, profit rise in second quarter

9961.HK TCOM.US
Jiumaojiu is a consumer brand

Online travel agent Trip.com Group Ltd. (9961.HK, TCOM.US) said on Wednesday its revenue rose 16% year-on-year to 14.8 billion yuan ($2.1 billion) in the second quarter of 2025, while its net profit increased 25% to 4.9 billion yuan.

The company attributed the revenue increase to strong tourism demand, particularly during holiday periods. Its accommodation reservation revenue reached 6.2 billion yuan, up 21% year-over-year. Transportation ticketing revenue rose 11% to 5.4 billion yuan, while package tour revenue climbed 5% to 1.1 billion yuan, and revenue from corporate travel management grew 9% to 692 million yuan.

Trip.com also disclosed that, under its share buyback program initiated in February, it had repurchased 7 million American depositary shares (ADS) through Aug. 27 at a cost of $400 million.

Following the results announcement, Trip.com’s U.S.-traded shares rose 8.6% in after-hours trading to $70.90. Its Hong Kong shares opened up 5.7% at HK$541.50 on Thursday.

By Lau Chi Hang

To subscribe to Bamboo Works weekly free newsletter, click here

, ,
,

Related Articles

RELATED ARTICLES

  1. What lurks beneath Trip.com's results surge
    ‘Revenge travel’ slowdown puts damper on Trip.com’s banner year
    9961.HK
  2. Trip.com’s overseas journey cruises ahead, as profit wobbles
    9961.HK TCOM.US
  3. BRIEF: NetEase revenue, profit rise in second quarter
    9999.HK NTES.US
  4. Klook goes against the flow with U.S. listing plan
  5. BRIEF: Niu’s second-quarter sales rise 36.6%
    NIU.US
  6. Tongcheng beefs up its hotel management, as Wanda buys more time
    0780.HK 0169.HK
  7. BRIEF: MGM China’s revenue, profit edge up in second quarter
    2282.HK
Discover hidden China stock gems in our weekly newsletter

Follow us

Facebook Twitter Linkedin Weixin Weibo Youtube

Subscribe to Our Free eNewsletter

Subscribe

Check out our content with some of our syndication partners

factiva

Recent Articles

Kelun-Biotech reported rising sales of its signature cancer drug

Precision cancer drugs show promise for Kelun-Biotech

The company reported rising sales of its signature cancer drug and could get national insurance coverage for other key products, potentially boosting full-year earnings Key Takeaways: Topline revenue actually fell…
6990.HK
Illustration of China's hydrogen battery industry

China plays defense on EV batteries, offense on hydrogen

China rolls out new rules restricting the export of cutting-edge technology for EV battery manufacturing. How will this affect Chinese battery makers setting up factories abroad? And hydrogen fuel cell maker Refire reports its revenue fell 10% in the first half of the year. What does this say about a Chinese sector that's getting huge government support, but has yet to find a mass audience?
3750.HK 2570.HK